Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium electronic
Typ dokumentu tisková chyba
PubMed
37752114
PubMed Central
PMC10522597
DOI
10.1038/s41408-023-00923-6
PII: 10.1038/s41408-023-00923-6
Knihovny.cz E-zdroje
- Publikační typ
- tisková chyba MeSH
Centro Integrado de Hematologia e Oncologia Hospital Mãe de Deus Porto Alegre Brazil
Department of Haematology Lille University Hospital Lille France
Department of Haematology University College Hospital London UK
Department of Hematology Seoul St Mary's Hospital The Catholic University of Korea Seoul South Korea
Department of Hematology University Hospital Hôtel Dieu Nantes France
Department of Hematology University of California at San Francisco San Francisco CA USA
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
Department of Internal Medicine Seoul National University Hospital Seoul South Korea
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil
Ividata Life Science Levallois Perret France
Myeloma Amyloidosis Center Japanese Red Cross Medical Center Tokyo Japan
Perth Blood Institute Murdoch University Perth Australia
Sanofi R and D Chilly Mazarin France
Sanofi R and D Vitry sur Seine France
Service d'Hématologie et Thérapie Cellulaire CHU and CIC Inserm 1402 Poitiers Cedex France
The National and Kapodistrian University of Athens Athens Greece
Translational Genomics Research Institute City of Hope Cancer Center Phoenix AZ USA
Citace poskytuje Crossref.org
